Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

(2014) Woonyoung Choi et al.   CANCER CELL

Clinical–Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Results From the National Cancer Data Base

(2014) Phillip J. Gray et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Functionalized Gold Nanorods for Thermal Ablation Treatment of Bladder Cancer

(2014) S. K. Cho et al.   Journal of Biomedical Nanotechnology

Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer

(2014) Ashish M. Kamat et al.   JOURNAL OF UROLOGY

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS)

(2013) J. Alfred Witjes et al.   BJU INTERNATIONAL

Effect of statin use on outcomes of non-muscle-invasive bladder cancer

(2013) Joseph J. Crivelli et al.   BJU INTERNATIONAL

Bacillus Calmette-Guérin immunotherapy for genitourinary cancer

(2013) Nilay M. Gandhi et al.   BJU INTERNATIONAL

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013

(2013) Marko Babjuk et al.   EUROPEAN UROLOGY

SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guérin

(2013) Eila C. Skinner et al.   JOURNAL OF UROLOGY

Efficacy and Safety of Photodynamic Therapy for Recurrent, High Grade Nonmuscle Invasive Bladder Cancer Refractory or Intolerant to Bacille Calmette-Guérin Immunotherapy

(2013) Joo Yong Lee et al.   JOURNAL OF UROLOGY

Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer

(2013) Colin P.N. Dinney et al.   JOURNAL OF UROLOGY

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guérin Instillation Therapy on the Quality of Life in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Prospective, Randomized, Phase II Trial

(2013) Paolo Gontero et al.   JOURNAL OF UROLOGY

Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non–muscle invasive bladder cancer

(2013) Andrew J. Lightfoot et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Adjuvant Intravesical Bacillus Calmette-Guérin Therapy and Survival Among Elderly Patients With Non–Muscle-Invasive Bladder Cancer

(2013) Benjamin A. Spencer et al.   Journal of Oncology Practice

Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis

(2012) Baerin B. Houghton et al.   BJU INTERNATIONAL

Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine

(2012) Koji Kawai et al.   CANCER SCIENCE

Diphtheria Toxin-Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer

(2012) X. Yang et al.   CLINICAL CANCER RESEARCH

Indication and timing of cystectomy in high-risk bladder cancer

(2012) Thierry Lebret et al.   CURRENT OPINION IN UROLOGY

ICUD-EAU International Consultation on Bladder Cancer 2012: Non–Muscle-Invasive Urothelial Carcinoma of the Bladder

(2012) Maximilian Burger et al.   EUROPEAN UROLOGY

Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer in the United States: Results from the National Cancer Data Base

(2012) Phillip J. Gray et al.   EUROPEAN UROLOGY

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

(2012) Jorg Oddens et al.   EUROPEAN UROLOGY

Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL

(2012) Goodwin Jinesh G. et al.   JOURNAL OF LEUKOCYTE BIOLOGY

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

(2012) James M. Burke et al.   JOURNAL OF UROLOGY

A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin

(2012) Mark Kowalski et al.   JOURNAL OF UROLOGY

Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial

(2012) Ashish M. Kamat et al.   JOURNAL OF UROLOGY

Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy

(2012) LaMont J. Barlow et al.   JOURNAL OF UROLOGY

Association of Polymorphisms in Oxidative Stress Genes with Clinical Outcomes for Bladder Cancer Treated with Bacillus Calmette-Guérin

(2012) Hua Wei et al.   PLoS One

Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer

(2012) C. Biot et al.   Science Translational Medicine

Recognition and Treatment of BCG Failure in Bladder Cancer

(2011) Andrew J. Lightfoot et al.   TheScientificWorldJOURNAL

Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer

(2010) Shiro Hinotsu et al.   BJU INTERNATIONAL

Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)

(2010) Renzo Colombo et al.   BJU INTERNATIONAL

Gene Signatures for the Prediction of Response to Bacillus Calmette-Guerin Immunotherapy in Primary pT1 Bladder Cancers

(2010) Y. J. Kim et al.   CLINICAL CANCER RESEARCH

Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Trial (30993)

(2010) Willem Oosterlinck et al.   EUROPEAN UROLOGY

Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group

(2010) Hirofumi Koga et al.   INTERNATIONAL JOURNAL OF UROLOGY

Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer

(2010) Kenneth G. Nepple et al.   JOURNAL OF UROLOGY

Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Plus Interferon α-2b Therapy for Nonmuscle Invasive Bladder Cancer in Patients With Prosthetic Devices

(2010) Henry M. Rosevear et al.   JOURNAL OF UROLOGY

Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway

(2010) Szu-Yuan Ping et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Smac mimetics as new cancer therapeutics

(2009) Derrick J. Chen et al.   ANTI-CANCER DRUGS

Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin

(2009) Jason R. Gee et al.   BJU INTERNATIONAL

Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?

(2009) Rocco Damiano et al.   BJU INTERNATIONAL

Bacillus Calmette-Guérin Is Superior to a Combination of Epirubicin and Interferon-α2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study

(2009) Miloš Duchek et al.   EUROPEAN UROLOGY

Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

(2009) Richard J. Sylvester et al.   EUROPEAN UROLOGY

Definition and management of patients with bladder cancer who fail BCG therapy

(2009) Frances M Martin et al.   Expert Review of Anticancer Therapy

Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance

(2009) Raffaele Addeo et al.   JOURNAL OF CLINICAL ONCOLOGY

HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management

(2009) Elizabeth M Gaughan et al.   BMC Urology

The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?

(2008) Jennifer Y. Wo et al.   BJU INTERNATIONAL

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer

(2008) Donald Lamm et al.   EUROPEAN UROLOGY SUPPLEMENTS

An Analysis of the Effect of Statin Use on the Efficacy of Bacillus Calmette-Guerin Treatment for Transitional Cell Carcinoma of the Bladder

(2008) Ryan K. Berglund et al.   JOURNAL OF UROLOGY